Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.12 · Revenue $35.77M · 3 analysts
Est. EPS $-0.11 · Revenue $48.50M · 3 analysts
Est. EPS $-0.39 · Revenue $199.13M · 6 analysts
Est. EPS $-0.02 · Revenue $62.98M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $62.9M | +699.0% | -61.9% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-204.6M | +64.0% | -1264.4% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +86.6% | +757.4% | +4.2% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -338.7% | +95.5% | -3554.0% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -325.3% | +95.5% | -3158.2% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-173.8M | -33.1% | -200.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -276.3% | +83.3% | -362.7% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 3.3% | +72.7% | +3129.8% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 6.95x | -23.1% | +12.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $594.8M | +10.0% | +22.0% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.60 vs -0.59 | -2.3% | -0.18 vs -0.14 | -27.1% |
| Revenue Surprise | $62.9M vs $58.9M | +6.9% | $31.7M vs $27.0M | +17.2% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Hattersley Gary | officer: CHIEF SCIENTIFIC OFFICER | Stock Option (Right to Buy) | D | 100,000 | $1.87 |
| Aug 19, 2026 | Hattersley Gary | officer: CHIEF SCIENTIFIC OFFICER | Class A Common Stock | A | 100,000 | $1.87 |
| Aug 19, 2026 | Hattersley Gary | officer: CHIEF SCIENTIFIC OFFICER | Class A Common Stock | D | 100,000 | $7.09 |
| Jul 15, 2026 | Sauvage Philippe | officer: Chief Financial Officer | Stock Option (Right to Buy) | D | 39,999 | $2.17 |
| Jul 15, 2026 | Sauvage Philippe | officer: Chief Financial Officer | Stock Option (Right to Buy) | D | 1 | $1.97 |
Operator: Hello, and welcome to Nuvation Bio's Second Quarter 2026 Financial Results and Business Update Call. Today's call is being recorded, and a replay will be available on the company's website. [Operator Instructions] Now I'd like to turn the call over to J R DeVita, Vice President of Corporate Development and Investor Relations at Nuvation Bio. Please go ahead. Robert DeVita: Thank you, and good morning, everyone. Earlier today, we issued a press release summarizing our financial results for the quarter ending June 30, 2026, and provided a business update. The press release is available on the Investors section of our website at nuvationbio.com. Today's call includes forward-looking statements, including statements about the therapeutic and commercial potential of IBTROZI and safusidenib, our development plans for safusidenib and our drug-drug conjugate platform, along with our plans for future updates from these programs, the components of our anticipated product revenue, expected milestone payments and our cash runway. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our quarterly report on Form 10-Q, which we filed with the U.S. Securities and Exchange Commission today. Joining me on today's call are our Founder, President and Chief Executive Officer, Dr. David Hung; our Chief Commercial Officer, Colleen Sjogren; and our Chief Financial Officer, Philippe Sauvage. Now I'll turn the call over to Dr. David Hung. David, please go ahead. David Hung: Thanks, J R. Good morning, everyone, and thank you all for joining us. I'm excited to discuss the continued progress we made across our business in the second quarter. IBTROZI delivered another strong quarter with net revenue growing 25% to $23.2 million, in line with the median estimate from our 10 covering analysts. Approximately 160 new patients started treatment with IBTROZI in the quarter, but importantly, about 85% of these starts were in the first-line setting, our highest percentage since launch only 12 months ago. While we believe that revenue is the metric that best reflects the health and trajectory of the business, we felt it was helpful to again provide new patient starts this quarter to give more color on positively shifting launch dynamics. I'd also like to provide you with 3 specific points of context to further frame our view of the launch today. First, we are executing on our commercial plan well, and we are now the ROS1 TKI market leader in both first-line and overall new patient starts. Second, we are expanding the ROS1 market beyond how it has been viewed historically with the majority of IBTROZI's growth coming from the first-line setting. And third, the promise of IBTROZI's clinical differentiation is being realized in the real world. Now I'll spend some time walking through …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
David T. Hung | Founder, President, Chief Executive Officer & Chairman | USD 1,202,100 | — | 1958 | Active |
Philippe Sauvage | Chief Financial Officer & Principal Financial Officer | USD 810,018 | Male | 1978 | Active |
Gary Hattersley | Chief Scientific Officer | USD 805,803 | — | 1967 | Active |
David Liu | Chief Medical Officer | USD 677,151 | — | 1970 | Active |
Colleen Sjogren | Chief Commercial Officer | USD 615,841 | Female | 1971 | Active |
David C. Hanley | Chief Technical Operations Officer | USD 586,040 | — | 1970 | Active |
Moses Makunje | Vice President of Finance and Principal Accounting & Financial Officer | — | Male | 1979 | Active |
Robert DeVita | Vice President of Corporate Development & Investor Relations | — | — | — | Active |
Kerry A. Wentworth | Chief Regulatory Officer | — | Female | 1973 | Active |
Stacy Markel | Chief People Officer | — | Female | 1965 | Active |
Stephen Dang | Chief Legal Officer & Corporate Secretary | — | — | — | Active |
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
Nuvation Bio (NUVB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The consensus price target hints at a 94.3% upside potential for Nuvation Bio (NUVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NEW YORK, July 22, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2026.
Nuvation Bio (NUVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
